Humalog® Mix75/25™ [75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid-acting blood glucose-lowering agent and insulin lispro protamine suspension, an intermediate-acting blood glucose-lowering agent.
Humalog Mix75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro, is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog Mix75/25 has a more rapid onset of glucose-lowering activity compared to Humulin 70/30 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.
Published Studies Related to Humalog Mix75 / 25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. [2010.05]
AIMS: The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in basal-bolus regimens in Type 1 diabetes... CONCLUSIONS: ILPS-treated patients with Type 1 diabetes achieved similar glycaemic control as insulin detemir-treated patients after 32 weeks. Glucose variability was similar. While weight gain and nocturnal hypoglycaemia rate were statistically higher with ILPS, the clinical relevance is unclear.
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]
CONCLUSIONS: Mix25 improves postprandial BG and yields a greater effect on BG excursions compared with monotherapy with glibenclamide. The timing of Mix25 did not impact the level of BG or BG fluctuations after meals, which may be important for individuals with changing dietary pattern.
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]
OBJECTIVE: The goal of this study was to compare the efficacy and safety profiles of biphasic insulin aspart 30 (30% soluble insulin aspart and 70% protaminated insulin aspart [BIAsp 30]) and biphasic insulin lispro 25 (25% soluble insulin lispro and 75% neutral protamine lispro [Mix25]) used in a BID injection regimen in patients with type 2 diabetes mellitus (DM). Also assessed was patients' preference for pen device--the NovoMix 30 FlexPen /NovoLog Mix 70/30 FlexPen (FlexPen) versus the Humalog Mix25 Pen/Humalog Mix75/25 Pen (Humalog Pen)... CONCLUSIONS: In this study, glycemic control with BIAsp 30 and Mix25 was found to be comparable in these patients with type 2 DM. Safety profiles were similar for both regimens. Patients preferred and experienced fewer problems with the FlexPen than the Humalog Pen.
Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. [2003.09]
CONCLUSIONS: Compared with treatment with Mix25 twice daily, treatment with Mix50 before breakfast and Mix25 before the evening meal resulted in better pp glycaemic control following a carbohydrate-rich meal, and similar fasting BG, A1C and incidence of hypoglycaemia in patients with type 2 diabetes.
Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. [2003.03]
OBJECTIVE: To compare the effects of Humalog Mix25 (Humalog Mix75/25 in the USA) (Mix25) and human insulin 30/70 (30/70) on the 24-hour inpatient plasma glucose (PG) profile in patients with type 2 diabetes mellitus (T2DM)... CONCLUSION: In patients with T2DM, Mix25 improved the 24-hour PG profile with lower postprandial PG excursions than with human insulin 30/70.
Clinical Trials Related to Humalog Mix75 / 25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus [Completed]
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA)
approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase
PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of
other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and
Humulin-R in order to determine if it improves the absorption of these insulins to more
closely mimic the body's natural increase in insulin in response to a meal.
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics [Withdrawn]
This is a randomized, parallel group comparison of the immunogenicity safety of Wockhardt's
Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue HumalogŪ and
HumalogŪ Mix in patients with Type 1 Diabetes Mellitus
HumalogŪ Mix50/50(tm) as a Treatment for Gestational Diabetes [Completed]
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use [Completed]
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose
of this study is to provide information on the use of insulin lispro in insulin pumps
(Continuous Subcutaneous Insulin Infusion [CSII]) compared to insulin aspart over 6 days of
pump reservoir in-use. The study will also compare the in-use characteristics of insulin
lispro infused at 6 days with insulin lispro infused at 2 days.
A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants [Completed]
BC106 is a molecule that when injected with insulin lispro may change the speed of
absorption of insulin lispro. The purpose of this study will be to evaluate the safety of
BC106 insulin lispro and any side effects that might be associated with it, blood levels of
insulin lispro after injection under the skin and how BC106 insulin lispro affects blood
sugar after injection under the skin. There is a minimum 7 day washout between single doses.